Workflow
太极集团: 太极集团2024年度独立董事述职报告-吴宪

Core Viewpoint - The independent director of Chongqing Taiji Industry (Group) Co., Ltd. has diligently fulfilled responsibilities in accordance with relevant laws and regulations, actively participating in the company's operations and decision-making processes to protect the interests of all shareholders, particularly minority shareholders [1][11]. Group 1: Independent Director Overview - The independent director, Wu Xian, has extensive experience in the pharmaceutical industry and has been serving as an independent director since May 10, 2023 [1]. - Wu Xian holds various positions, including chairman of the remuneration and assessment committee, member of the strategy committee, and member of the nomination committee [2]. Group 2: Annual Performance Overview - The company held two shareholder meetings during the reporting period, with the independent director attending all meetings and participating in the review of 11 proposals [2]. - The independent director attended all eight board meetings, actively participating in discussions and voting in favor of all proposals without any objections or abstentions [2][3]. Group 3: Key Focus Areas - The independent director emphasized the importance of fair and reasonable pricing in related party transactions, ensuring that these transactions do not affect the company's independence and are in the best interest of all shareholders [7][8]. - The company adhered to legal requirements in disclosing financial reports and internal control evaluations, accurately reflecting its financial status and operational results [8][9]. - The independent director supported the reappointment of Tianjian Accounting Firm for the 2024 financial report and internal control audit, ensuring compliance with auditing standards [9]. Group 4: Recommendations and Suggestions - The independent director provided insights on enhancing quality management and promoting technological innovation within the company's production capabilities [10]. - Suggestions were made to increase investment in evidence-based medicine research and the development of innovative traditional Chinese medicine products [10].